Detalhe da pesquisa
1.
Fundamental immune-oncogenicity trade-offs define driver mutation fitness.
Nature
; 606(7912): 172-179, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35545680
2.
Targeting T Cell Co-receptors for Cancer Therapy.
Immunity
; 44(5): 1069-78, 2016 05 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-27192570
3.
Integration of peripheral blood- and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinoma.
J Pathol
; 261(3): 349-360, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37667855
4.
Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy.
Oncologist
; 28(4): 351-357, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36745014
5.
Author Correction: Fundamental immune-oncogenicity trade-offs define driver mutation fitness.
Nature
; 606(7914): E5, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35641605
6.
Clinical implications of drug-induced liver injury in early-phase oncology clinical trials.
Cancer
; 126(22): 4967-4974, 2020 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32809222
7.
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
N Engl J Med
; 377(14): 1345-1356, 2017 10 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28889792
8.
Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade.
Ann Surg Oncol
; 27(4): 1180-1188, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31848819
9.
Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience.
Oncologist
; 24(5): e196-e197, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30910868
10.
Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade.
Gynecol Oncol
; 152(2): 251-258, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30470581
11.
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
N Engl J Med
; 373(1): 23-34, 2015 Jul 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-26027431
12.
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.
Lancet Oncol
; 17(11): 1590-1598, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27733243
13.
Immune modulation in cancer with antibodies.
Annu Rev Med
; 65: 185-202, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24188664
14.
Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis.
Oncologist
; 21(7): 848-54, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27286787
15.
Nivolumab plus ipilimumab in advanced melanoma.
N Engl J Med
; 369(2): 122-33, 2013 Jul 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-23724867
16.
Checkpoint Blockade for the Treatment of Advanced Melanoma.
Cancer Treat Res
; 167: 231-50, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26601865
17.
Progression of RAS-mutant leukemia during RAF inhibitor treatment.
N Engl J Med
; 367(24): 2316-21, 2012 Dec 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-23134356
18.
Immunologic correlates of the abscopal effect in a patient with melanoma.
N Engl J Med
; 366(10): 925-31, 2012 Mar 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-22397654
19.
Early on-treatment assessment of T-cells, cytokines and tumor DNA with adaptively-dosed nivolumab + ipilimumab: final results from the phase 2 ADAPT-IT study.
Clin Cancer Res
; 2024 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38767650
20.
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.
Cancer
; 119(20): 3687-95, 2013 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23913718